Global Blood Therapeutics
181 Oyster Point Blvd
South San Francisco
California
94080
United States
Website: http://www.gbt.com/
Email: info@gbt.com
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
260 articles with Global Blood Therapeutics
-
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
5/12/2022
Global Blood Therapeutics, Inc. announced five abstracts related to its sickle cell disease programs will be presented at the European Hematology Association 2022 Hybrid Congress.
-
GBT Announces Participation in Upcoming Investor Conferences - May 05, 2022
5/5/2022
Global Blood Therapeutics, Inc. announced that it will participate in fireside chats at the following investor conferences.
-
GBT Announces New Employment Inducement Grants - May 05, 2022
5/5/2022
Global Blood Therapeutics, Inc. announced that on May 1, 2022, the compensation committee of GBT’s board of directors granted 14 new employees restricted stock units for an aggregate of 46,400 shares of the company’s common stock.
-
GBT Reports First Quarter 2022 Financial Results
5/4/2022
Global Blood Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022, and recent business progress.
-
GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
4/27/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close.
-
GBT Announces New Employment Inducement Grants - Apr 07, 2022
4/7/2022
Global Blood Therapeutics, Inc. announced that on April 1, 2022, the compensation committee of GBT’s board of directors granted 21 new employees restricted stock units for an aggregate of 64,050 shares of the company’s common stock.
-
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
3/24/2022
Global Blood Therapeutics, Inc. announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T.
-
GBT Announces New Employment Inducement Grants - Mar 10, 2022
3/10/2022
Global Blood Therapeutics, Inc. announced that on March 1, 2022, the compensation committee of GBT’s board of directors granted 19 new employees restricted stock units for an aggregate of 42,380 shares of the company’s common stock.
-
On Wednesday, Massachusetts-based ConforMIS said it was suspending all distribution of its orthopedic medical devices to Russia and any Russian-based entities.
-
GBT Announces Participation in Upcoming Investor Conferences - Feb 28, 2022
2/28/2022
Global Blood Therapeutics, Inc. announced that it will participate in virtual fireside chats at the following investor conferences.
-
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
2/23/2022
Global Blood Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021, and recent business progress.
-
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
2/16/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2021 financial results on Wednesday, February 23, 2022, after U.S. financial markets close.
-
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
2/16/2022
Global Blood Therapeutics, Inc. announced the European Commission has granted Marketing Authorization for Oxbryta® for the treatment of hemolytic anemia due to sickle cell disease in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
-
GBT Announces New Employment Inducement Grants - Feb 03, 2022
2/3/2022
Global Blood Therapeutics, Inc. announced that on February 1, 2022, the compensation committee of GBT’s board of directors granted 21 new employees options to purchase an aggregate of 33,290 shares of the company’s common stock with a per share exercise price of $29.33 and restricted stock units for an aggregate of 80,100 shares of the company’s common stock.
-
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
1/10/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Drug Administration (FDA), is now available through GBT’s specialty pharmacy partner network in the United States.
-
GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/4/2022
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 11:15 a.m. E.T.
-
Although the U.S. FDA largely cleared its calendar ahead of the holidays, it still has a couple open PDUFA dates leading up to January 1, 2022. Here’s a look.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
U.S. FDA Approves Supplemental New Drug Application for Expanded Indication of Oxbryta® (voxelotor) for Children as Young as 4 Years of Age with Sickle Cell Disease
12/17/2021
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of a supplemental New Drug Application (sNDA) for Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in children ages 4 to less than 12 years.
-
Shares of Global Blood Therapeutics were up more than 10% in late-afternoon trading following regulatory approval of a supplemental New Drug Application for oral Oxbryta (voxelotor) tablets for the treatment of pediatric sickle cell disease.